Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostic & Research Stocks to Buy Now (2022)

Top diagnostic & research stocks in 2022 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

Sotera Health Co (NASDAQ:SHC) is the top diagnostic & research stock with a Zen Score of 61, which is 28 points higher than the diagnostic & research industry average of 33. It passed 20 out of 33 due diligence checks and has strong fundamentals. Sotera Health Co has seen its stock lose -72.67% over the past year, underperforming other diagnostic & research stocks by -42 percentage points.

Sotera Health Co has an average 1 year price target of $15.86, an upside of 124.6% from Sotera Health Co's current stock price of $7.06.

Sotera Health Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 8 analysts covering Sotera Health Co, 0% have issued a Strong Buy rating, 12.5% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 12.5% have issued a Strong Sell.

Co Diagnostics (NASDAQ:CODX) is the second best diagnostic & research stock with a Zen Score of 57, which is 24 points higher than the diagnostic & research industry average of 33. It passed 18 out of 33 due diligence checks and has strong fundamentals. Co Diagnostics has seen its stock lose -61.01% over the past year, underperforming other diagnostic & research stocks by -30 percentage points.

Co Diagnostics has an average 1 year price target of $7.00, an upside of 111.48% from Co Diagnostics's current stock price of $3.31.

Co Diagnostics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Co Diagnostics, 0% have issued a Strong Buy rating, 50% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Quidelortho (NASDAQ:QDEL) is the third best diagnostic & research stock with a Zen Score of 56, which is 23 points higher than the diagnostic & research industry average of 33. It passed 18 out of 33 due diligence checks and has strong fundamentals. Quidelortho has seen its stock lose -46.47% over the past year, underperforming other diagnostic & research stocks by -16 percentage points.

Quidelortho has an average 1 year price target of $104.00, an upside of 43.65% from Quidelortho's current stock price of $72.40.

Quidelortho stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Quidelortho, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 33.33% have issued a Strong Sell.

Out of 9 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

Koninklijke Philips Nv (NYSE:PHG) has an annual dividend yield of 6.11%, which is 4 percentage points higher than the diagnostic & research industry average of 1.71%. Koninklijke Philips Nv's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Koninklijke Philips Nv's dividend has not shown consistent growth over the last 10 years.

Koninklijke Philips Nv's dividend payout ratio of 24.8% indicates that its high dividend yield is sustainable for the long-term.

Psychemedics (NASDAQ:PMD) has an annual dividend yield of 3%, which is 1 percentage points higher than the diagnostic & research industry average of 1.71%. Psychemedics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Psychemedics's dividend has not shown consistent growth over the last 10 years.

Psychemedics's dividend payout ratio of -57.1% indicates that its dividend yield might not be sustainable for the long-term.

National Research (NASDAQ:NRC) has an annual dividend yield of 2.12%, which is the same as the diagnostic & research industry average of 1.71%. National Research's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. National Research's dividend has not shown consistent growth over the last 10 years.

National Research's dividend payout ratio of 50.3% indicates that its dividend yield is sustainable for the long-term.

Diagnostic & research stocks were down -0.84% in the last day, and up 6.44% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Sotera Health Co has a valuation score of 86, which is 50 points higher than the diagnostic & research industry average of 36. It passed 6 out of 7 valuation due diligence checks.

Sotera Health Co's stock has dropped -72.67% in the past year. It has underperformed other stocks in the diagnostic & research industry by -42 percentage points.

Syneos Health (NASDAQ:SYNH) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Syneos Health has a valuation score of 86, which is 50 points higher than the diagnostic & research industry average of 36. It passed 6 out of 7 valuation due diligence checks.

Syneos Health's stock has dropped -41.86% in the past year. It has underperformed other stocks in the diagnostic & research industry by -11 percentage points.

Quidelortho (NASDAQ:QDEL) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Quidelortho has a valuation score of 86, which is 50 points higher than the diagnostic & research industry average of 36. It passed 6 out of 7 valuation due diligence checks.

Quidelortho's stock has dropped -46.47% in the past year. It has underperformed other stocks in the diagnostic & research industry by -16 percentage points.